display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC CA184-156
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC IMpower-133
durvalumab based treatment
durvalumab plus etoposide and platin CASPIAN ...
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-604
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC CASPIAN ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons